RETATRUTIDE 60mg

Retatrutide – Research Compound Description

Retatrutide is a next-generation triple-agonist research peptide designed to activate three key metabolic receptors: GLP-1 (Glucagon-Like Peptide-1), GIP (Glucose-Dependent Insulinotropic Polypeptide), and Glucagon receptors. This multi-pathway mechanism makes retatrutide a compound of strong interest in advanced metabolic and obesity-related research.

By targeting GLP-1 and GIP receptors, retatrutide is studied for its role in appetite regulation, insulin response, and glucose metabolism, while glucagon receptor activation is researched for its potential involvement in energy expenditure and fat utilization. The combined agonism distinguishes retatrutide from single- or dual-agonist peptides.

Key Research Focus Areas

• Metabolic function and energy balance
• Weight-management and adipose tissue research
• Glucose regulation and insulin sensitivity studies
• Appetite and satiety signaling pathways

Compound Characteristics

• Peptide Class: Triple-agonist research peptide
• Receptor Targets: GLP-1, GIP, Glucagon
• Research Use: Laboratory and scientific research only

Important Notice

Retatrutide is intended strictly for research purposes only. It is not approved for human or veterinary use, consumption, diagnosis, or treatment of any medical condition.

This compound should be handled only by qualified professionals in controlled research environments, in accordance with all applicable laws and regulations.